In summary, in the context of a still GW-572016 in vivo limited scientific evidence base, our study and meta-analysis provide data supporting a differential role of the estrogen hydroxylation pathway in
prostate cancer development. The small sample size of our original study prevents us from drawing strong conclusions, but the results of our meta-analysis including the second study provide us with greater evidence in support of the investigated association and the need for further studies. References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55: 74–108.CrossRefPubMed 2. Giovannucci E: Epidemiologic characteristics of prostate cancer. Cancer 1995, (75) : 1766–77. 3. Bosland MC: The role of steroid hormones in prostate cancerogenesis. J Natl Cancer Inst Momogr
2000, 27: 39–66. 4. Diamandis EP, Yu H: Does prostate cancer start at puberty? Clin Lab Anal 1996, 10 (6) : 468–9.CrossRef 5. Barba M, Terrenato I, Schünemann H, Fuhrman B, Sperati F, Teter B, Gallucci M, D’Amato A, Muti P: Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results from a Case-control Study. Urology 2008, 72 (1) : 183–7.CrossRefPubMed 6. Carruba: Estrogens and Mechanisms of Prostate Cancer Progression. Ann N Y Acad Sci 2006, 1089: GSK126 research buy 201–7.CrossRefPubMed 7. Bosland MC, Ford H, Horton LI: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley
Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylbestrol. Carcinogenesis 1995, 16: 1311–7.CrossRefPubMed 8. Ho SM, Lane K: Sex hormone-induction and dietary modulation of prostatic adenocarcinoma (PA) in animal models. Urol Oncol 1996, 2: 110–5. 9. Ayala AG, Roj Y: Prostatic intraepithelial neoplasia: recent evidence. Arch Pathol Lab Med 2007, 131 (8) : 1257–31.PubMed Cobimetinib 10. Lotinum P, West K, Gibson KJ, Turner RT: Tissue-selective effects of continuous release of 2-hydrohyestrone and 16α-hydroxyestrone on bone, uterus and mammary gland in ovariectorized Luminespib mw growing rats. J Endocrinol 2001, 170: 165–174.CrossRef 11. Suto A, Bradlow H, Wong GY, Osborne MP, Telang NT: Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 1993, 27: 193–202.CrossRefPubMed 12. Telang NT, Suto A, Wong GY, Osborn MP, Bradlow HL: Induction by estrogen metabolite 16α-OHE1 of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992, 84: 634–8.CrossRefPubMed 13. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J, Schünemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L: Urinary estrogen metabolites and prostate cancer: a case-control study in the United States.